[PDF][PDF] A renal cell carcinoma tumorgraft platform to advance precision medicine
Cell reports, 2021•cell.com
Renal cell carcinoma (RCC) encompasses a heterogenous group of tumors, but
representative preclinical models are lacking. We previously showed that patient-derived
tumorgraft (TG) models recapitulate the biology and treatment responsiveness. Through
systematic orthotopic implantation of tumor samples from 926 ethnically diverse individuals
into non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) mice, we
generate a resource comprising 172 independently derived, stably engrafted TG lines from …
representative preclinical models are lacking. We previously showed that patient-derived
tumorgraft (TG) models recapitulate the biology and treatment responsiveness. Through
systematic orthotopic implantation of tumor samples from 926 ethnically diverse individuals
into non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) mice, we
generate a resource comprising 172 independently derived, stably engrafted TG lines from …
Summary
Renal cell carcinoma (RCC) encompasses a heterogenous group of tumors, but representative preclinical models are lacking. We previously showed that patient-derived tumorgraft (TG) models recapitulate the biology and treatment responsiveness. Through systematic orthotopic implantation of tumor samples from 926 ethnically diverse individuals into non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) mice, we generate a resource comprising 172 independently derived, stably engrafted TG lines from 148 individuals. TG lines are characterized histologically and genomically (whole-exome [n = 97] and RNA [n = 102] sequencing). The platform features a variety of histological and oncogenotypes, including TCGA clades further corroborated through orthogonal metabolomic analyses. We illustrate how it enables a deeper understanding of RCC biology; enables the development of tissue- and imaging-based molecular probes; and supports advances in drug development.
cell.com